Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $43 |
| Triangulated Fair Value | $44 |
| 12-mo Scenario PWEV | $44 |
| Implied Return | +3% |
| Forward P/E | 12.7x |
| Market Cap | $63B |
| 52-Week Range | $44 – $110 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate' (8% weight) — targets $77, +81% vs spot. It needs the multiple to hold or expand.
The dashboard below is the whole argument on one page: spot ($43) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' (20%) — targets $19, -55% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
P/E Multiple explains 71% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.12 vs analyst floor -0.04 → delta +0.15 (n=18 mgmt / 11 Q&A; 6th pctile across the S&P book, z -1.4).
Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.12 | -0.04 | +0.15 |
| 2025Q4 | +0.54 | +0.09 | +0.44 |
| 2025Q3 | +0.66 | +0.55 | +0.11 |
| 2025Q2 | +0.49 | +0.40 | +0.09 |
News (last 365d, 1000 articles): avg ticker sentiment +0.06 (bullish 13% / bearish 13%)
Scenario Analysis
The tree runs from a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($19) to a 'Bull — Re-Rate' bull case ($77); the probability-weighted blend (PWEV $44) is +2% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Reimbursement / Competition / GLP-1 Procedure Hit | 20% | $19 | -55% |
| Hospital-Capex / Utilization Recession | 17% | $33 | -24% |
| Base — Procedure Volume + Innovation | 35% | $45 | +6% |
| Growth — New-Product Cycle / Penetration | 20% | $61 | +43% |
| Bull — Re-Rate | 8% | $77 | +81% |
| Probability-Weighted (PWEV) | — | $44 | +2% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $19). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 19.22; probability: 0.2.
- Hospital-Capex / Utilization Recession (17%, $33). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising. Drivers — implied_target: 32.64; probability: 0.17.
- Base — Procedure Volume + Innovation (35%, $45). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns. Drivers — implied_target: 45.33; probability: 0.35.
- Growth — New-Product Cycle / Penetration (20%, $61). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 61.2; probability: 0.2.
- Bull — Re-Rate (8%, $77). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration. Drivers — implied_target: 77.29; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $39 | -8% |
| Peer P/E re-rate | multiple | $64 | +50% |
| Peer EV/Revenue re-rate | multiple | $59 | +38% |
| Scenario PWEV | multiple | $44 | +2% |
| DCF (5-year + terminal) | cash flow + terminal × | $41 | -5% |
| Triangulated (weighted) | — | $44 | +3% |
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $39 and 41% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (71% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 11x terminal FCF multiple → $41. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 19.03x) implies $64. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is wide (genuine disagreement — low valuation confidence).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Medical Devices & Equipment | $20.6B | 100% | 6% | 27% | 13x | 5% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | procedure volumes + product-innovation cycle + hospital capital spending |
| net_debt_or_cash_b | -9.51 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.05 |
| div_yield | None |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | reimbursement / competition / GLP-1 procedure hit |
| upside | new-product cycle + penetration |
Industry Context — Health Devices Tools
This name sits in the Health Devices Tools as a medical_devices. procedure volumes + product-innovation cycle + hospital capital spending Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: TMO (life_science_tools) · ABT (medical_devices) · ISRG (medical_devices) · DHR (life_science_tools) · SYK (medical_devices) · MDT (medical_devices) · BSX (medical_devices) · EW (medical_devices) · IDXX (animal_health) · BDX (medical_devices) · A (life_science_tools) · WAT (life_science_tools) · ZTS (animal_health) · IQV (life_science_tools) · GEHC (medical_devices) · RMD (medical_devices) · DXCM (medical_devices) · VEEV (life_science_tools) · MTD (life_science_tools) · WST (medical_devices) · STE (medical_devices) · ZBH (medical_devices) · COO (medical_devices) · SOLV (medical_devices) · ALGN (medical_devices) · RVTY (medical_devices) · BAX (medical_devices) · PODD (medical_devices) · CRL (life_science_tools) · TECH (life_science_tools)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Reimbursement / Funding / Utilization Reset | 37% | 37% | |
| Mid-Cycle — Procedure & R&D Demand | 35% | 35% | |
| Upside — Innovation / Recovery Re-Rate | 28% | 28% |
On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $22B | $6B | $1B | $1B | $5B | $5B |
| FY+2 | $23B | $7B | $1B | $1B | $6B | $5B |
| FY+3 | $24B | $7B | $1B | $1B | $6B | $5B |
| FY+4 | $25B | $7B | $1B | $1B | $6B | $4B |
| FY+5 | $26B | $8B | $1B | $1B | $6B | $4B |
| Terminal | — | — | — | — | $6B × 11x | $47B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $23B + PV(terminal) $47B = EV $70B; + net cash → equity $60B ÷ diluted shares 1.49B = $41/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $58/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 22% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| ABT | 4.191x | 17.01x | 6% | 14% |
| ISRG | 12.95x | 38.61x | 6% | 31% |
| SYK | 5.26x | 21.05x | 6% | 18% |
| MDT | 3.35x | 13.51x | 6% | 22% |
| Median | 4.7255x | 19.03x | — | — |
Peer-median fwd P/E → $64; EV/Rev → $59.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $41 | 41% | $17 |
| Scenario PWEV | $44 | 29% | $13 |
| Monte Carlo median | $39 | 18% | $7 |
| Peer P/E | $64 | 12% | $8 |
| Triangulated | — | 100% | $44 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 7.7x | 9.3x | 11.0x | 12.6x | 14.3x |
|---|---|---|---|---|---|
| 6% | $34 | $39 | $45 | $50 | $55 |
| 8% | $33 | $37 | $43 | $47 | $52 |
| 8% | $31 | $36 | $41 | $45 | $50 |
| 10% | $30 | $34 | $39 | $43 | $48 |
| 10% | $28 | $33 | $37 | $41 | $46 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $31 | $33 | $36 | $38 | $40 |
| -1.5pp | $34 | $36 | $38 | $40 | $43 |
| +0.0pp | $36 | $38 | $41 | $43 | $45 |
| +1.5pp | $38 | $41 | $43 | $46 | $49 |
| +3.0pp | $41 | $44 | $46 | $49 | $52 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Revenue CAGR ±3pp | $36 | $46 | $11 |
| Op margin ±3pp | $36 | $45 | $10 |
| Terminal × ±15% | $36 | $45 | $9 |
| WACC ±1pp | $39 | $43 | $4 |
| FCF conversion ±10% | $41 | $41 | $0 |
Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 13x)
| Multiple | 9.1x | 11.0x | 13.0x | 14.9x | 16.9x |
|---|---|---|---|---|---|
| SoP/share | $120 | $146 | $174 | $200 | $228 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 11×, FY+5 revenue $26B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
The valuation is multiple-dependent (71% of variance); a de-rating toward the DCF anchor ($41) implies -5%.
Fact / Inference / Speculation
- FACT: Spot $43; 52-week range $44–$110; engine rating HOLD; base-case target $44 (+2%).
- INFERENCE: Triangulated FV $44 (+3%). P/E Multiple explains 71% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
- SPECULATION: At current prices the embedded bet is that the multiple holds or expands — P/E Multiple carries 71% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $44 (+3% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple (71% of variance) — fundamentally a multiple/regime call. SBC runs —M TTM (disclosed in the appendix).